The Role of Gut Microbiome on Glioblastoma Oncogenesis and Malignant Evolution DOI Open Access
Zahurin Mohamed, Qiong Wu, Maria A. Jacome

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(7), С. 2935 - 2935

Опубликована: Март 24, 2025

Glioblastoma (GBM) remains the most aggressive primary brain tumor, with poor survival outcomes and treatment limited to maximal safe surgical resection, chemotherapy temozolomide, radiotherapy. While immunotherapy targeted treatments show promise, therapeutic resistance disease progression remain major challenges. This is partly due GBM's classification as a "cold tumor" low mutational burden lack of distinct molecular targets for drug delivery that selectively spare healthy tissue. Emerging evidence highlights gut microbiota key player in cancer biology, influencing both glioma development response. review explores intersectionality between microbiome GBM, beginning an overview composition its broader implications pathophysiology. We then examine how specific microbial populations contribute oncogenesis, modulating immune responses, inflammation, metabolic pathways drive tumor initiation progression. Additionally, we discuss microbiome's role resistance, including impact on chemotherapy, radiotherapy, efficacy. Given influence outcomes, evaluate emerging strategies modulate flora, such probiotics, dietary interventions, microbiota-based therapeutics, enhance therapy response GBM patients. Finally, address challenges future directions, emphasizing need standardized methodologies, mechanistic studies, clinical trials validate microbiota-targeted interventions neuro-oncology. By integrating research into paradigms, may unlock novel avenues improve patient outcomes.

Язык: Английский

Modulation of the Neuro–Cancer Connection by Metabolites of Gut Microbiota DOI Creative Commons
Alice Njolke Mafe, Dietrich Büsselberg

Biomolecules, Год журнала: 2025, Номер 15(2), С. 270 - 270

Опубликована: Фев. 12, 2025

The gut-brain-cancer axis represents a novel and intricate connection between the gut microbiota, neurobiology, cancer progression. Recent advances have accentuated significant role of microbiota metabolites in modulating systemic processes that influence both brain health tumorigenesis. This paper explores emerging concept metabolite-mediated modulation within connection, focusing on key such as short-chain fatty acids (SCFAs), tryptophan derivatives, secondary bile acids, lipopolysaccharides (LPS). While microbiota's impact immune regulation, neuroinflammation, tumor development is well established, gaps remain grasping how specific contribute to neuro-cancer interactions. We discuss with potential implications for neurobiology cancer, indoles polyamines, which yet be extensively studied. Furthermore, we review preclinical clinical evidence linking dysbiosis, altered metabolite profiles, tumors, showcasing limitations research gaps, particularly human longitudinal studies. Case studies investigating microbiota-based interventions, including dietary changes, fecal transplantation, probiotics, demonstrate promise but also indicate hurdles translating these findings therapies. concludes call standardized multi-omics approaches bi-directional frameworks integrating microbiome, neuroscience, oncology develop personalized therapeutic strategies patients.

Язык: Английский

Процитировано

1

The Role of the Gut Microbiota in Modulating Signaling Pathways and Oxidative Stress in Glioma Therapies DOI Open Access
Aleksandra Krawczyk,

Gabriela Elzbieta Sladowska,

Barbara Strzałka‐Mrozik

и другие.

Cancers, Год журнала: 2025, Номер 17(5), С. 719 - 719

Опубликована: Фев. 20, 2025

Tumors of the central nervous system (CNS), especially gliomas, pose a significant clinical challenge due to their aggressive nature and limited therapeutic options. Emerging research highlights critical role gut microbiota in regulating CNS health disease. The composition is essential for maintaining homeostasis, as it modulates immune responses, oxidative status, neuroinflammation. microbiota–gut–brain axis, bidirectional communication network, plays pivotal cancer disease treatment, exerting its influence through neural, endocrine, immunological, metabolic pathways. Recent studies suggest that influences solidification tumor microenvironment dysbiosis may promote glioma development by modulating systemic inflammation stress, which contributes tumorigenesis progression. This review interrogates impact on glioma, focusing pathways such NF-κB, MAPK, PI3K/Akt/mTOR, Kynurenine/AhR drive proliferation, evasion, therapy resistance. Furthermore, we explore emerging strategies, including probiotics microbiota-based interventions, show potential these enhancing immunotherapies checkpoint inhibitors. By multifaceted interactions between microbiota, tumors, this microbiota-targeted therapies manipulation complement enhance current treatments.

Язык: Английский

Процитировано

1

The oncobiome; what, so what, now what? DOI Open Access

Munawar Abbas,

Mark Tangney

Microbiome Research Reports, Год журнала: 2025, Номер 4(1)

Опубликована: Фев. 27, 2025

Microbial communities inhabiting various body sites play critical roles in the initiation, progression, and treatment of cancer. The gut microbiota, a highly diverse microbial ecosystem, interacts with immune cells to modulate inflammation surveillance, influencing cancer risk therapeutic outcomes. Local tissue microbiota may impact transition from premalignant states malignancy. Characterization intratumoral increasingly reveals distinct microbiomes that influence tumor growth, responses, efficacy. Various bacteria species have been reported therapies through mechanisms such as altering drug metabolism shaping microenvironment (TME). For instance, or bacterial enzymatic activity can convert prodrugs into active forms, enhancing effects or, conversely, inactivating small-molecule chemotherapeutics. Specific also linked improved responses immunotherapy, underscoring microbiome’s role Furthermore, unique signatures patients, compared healthy individuals, demonstrate diagnostic potential microbiota. Beyond gut, tumor-associated local affect therapy by inflammation, resistance. This review explores multifaceted relationships between cancer, focusing on their modulating TME, activation, members represents promising avenue for advancing precision oncology improving patient By leveraging biomarkers interventions, new strategies be developed optimize diagnosis treatment.

Язык: Английский

Процитировано

0

The Role of Gut Microbiome on Glioblastoma Oncogenesis and Malignant Evolution DOI Open Access
Zahurin Mohamed, Qiong Wu, Maria A. Jacome

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(7), С. 2935 - 2935

Опубликована: Март 24, 2025

Glioblastoma (GBM) remains the most aggressive primary brain tumor, with poor survival outcomes and treatment limited to maximal safe surgical resection, chemotherapy temozolomide, radiotherapy. While immunotherapy targeted treatments show promise, therapeutic resistance disease progression remain major challenges. This is partly due GBM's classification as a "cold tumor" low mutational burden lack of distinct molecular targets for drug delivery that selectively spare healthy tissue. Emerging evidence highlights gut microbiota key player in cancer biology, influencing both glioma development response. review explores intersectionality between microbiome GBM, beginning an overview composition its broader implications pathophysiology. We then examine how specific microbial populations contribute oncogenesis, modulating immune responses, inflammation, metabolic pathways drive tumor initiation progression. Additionally, we discuss microbiome's role resistance, including impact on chemotherapy, radiotherapy, efficacy. Given influence outcomes, evaluate emerging strategies modulate flora, such probiotics, dietary interventions, microbiota-based therapeutics, enhance therapy response GBM patients. Finally, address challenges future directions, emphasizing need standardized methodologies, mechanistic studies, clinical trials validate microbiota-targeted interventions neuro-oncology. By integrating research into paradigms, may unlock novel avenues improve patient outcomes.

Язык: Английский

Процитировано

0